How to Make Long-Lasting Injections for Multiple Sclerosis Treatment

A patent for a slow-release version of the MS drug glatiramer acetate, designed to be injected once every week to six months instead of daily.

What it covers

This patent describes a way to package the drug glatiramer acetate—commonly used for multiple sclerosis—into a 'depot' form. Instead of the drug being absorbed by the body all at once, it is trapped inside a carrier material, such as biodegradable microspheres made of polymers like PLGA. This allows the medication to be released slowly into the patient's system over a period ranging from one week to six months. By using a double-emulsification process, the drug is kept in an internal phase that gradually leaks out, aiming to maintain therapeutic levels in the blood without the need for daily injections.

What it doesn't cover

• —Does not cover the chemical structure of glatiramer acetate itself, which is a known drug.
• —Does not cover immediate-release formulations that are injected daily.
• —Does not cover non-depot delivery methods like oral pills or intravenous drips.
• —Does not cover specific medical devices or needles used to deliver the injection.

The clever bit

The innovation lies in stabilizing a complex mixture of amino acids (glatiramer) within a polymer matrix to ensure it releases steadily over months without degrading or losing its therapeutic effectiveness.

Why it matters

Glatiramer acetate is a standard treatment for multiple sclerosis, but it traditionally requires painful daily injections. This patent represents a significant effort to improve patient compliance and quality of life by reducing the frequency of dosing. If successful, it could shift the market standard from daily self-administration to infrequent clinical visits.

Real-world examples

• 1.Experimental long-acting glatiramer acetate depot injections
• 2.Slow-release polymer-based drug delivery systems for autoimmune diseases